AI Verdict
MC has stronger fundamentals based on our AI analysis.
MC vs MBRX Fundamental Comparison
| Metric | MC | MBRX |
|---|---|---|
| Revenue | $1.5B | $0.0 |
| Net Income | $233.0M | $-33.6M |
| Net Margin | 15.4% | N/A |
| ROE | 41.0% | -223.6% |
| ROA | 13.4% | -151.7% |
| Current Ratio | N/A | 1.41x |
| Debt/Equity | 0.00x | 0.00x |
| EPS | $0.75 | N/A |
Green = Better metric | Red = Weaker metric
You Might Also Compare
MC vs MBRX: Frequently Asked Questions
Is MC or MBRX a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), MC has stronger fundamentals. MC is rated BUY (78% confidence) while MBRX is rated STRONG SELL (95% confidence). This is not investment advice.
How does MC compare to MBRX fundamentally?
Moelis & Co has ROE of 41.0% vs Moleculin Biotech, Inc.'s -223.6%. Net margins are 15.4% vs N/A respectively.
Which stock pays higher dividends, MC or MBRX?
MC has a dividend yield of N/A or no dividend while MBRX has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in MC or MBRX for long term?
For long-term investing, consider that MC has BUY rating with 78% confidence, while MBRX has STRONG SELL rating with 95% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about MC vs MBRX?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For MC vs MBRX, the AI consensus favors MC based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.